Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response

World Journal of Gastroenterology

Volumn 16, Issue 19, 2010, Pages 2407-2410

  Bodlaj, Gerd ^a   Hubmann, Rainer ^a   Saleh, Karim ^a   Stojakovic, Tatjana ^b   Biesenbach, Georg ^a   Berg, Jörg ^a  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Alkaline phosphatase; Chronic hepatitis c; Pegylated interferon; Predictor; Relapse

Indexed keywords

ALKALINE PHOSPHATASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RELAPSE; TREATMENT RESPONSE;

EID: 77953175966     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i19.2407     Document Type: Article

References (16)

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74-S83
2. Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997; 26: 521-526
3. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology 2002; 36: S3-S20
4. Xie Y, Xu DZ, Lu ZM, Luo KX, Jia JD, Wang YM, Zhao GZ, Zhang SL, Zhang DZ. Impact of virus genotype on inter-feron treatment of patients with chronic hepatitis C: a multi-center controlled study. Hepatobiliary Pancreat Dis Int 2004; 3: 369-374
5. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36: S114-S120
6. Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 2006; 26: 1119-1125
7. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat 2003; 10: 16-22
8. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-793
9. Medina J, García-Buey L, Moreno-Monteagudo JA, Trapero-Marugán M, Moreno-Otero R. Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003; 60: 135-143
10. Fukutomi T, Fukutomi M, Iwao M, Watanabe H, Tanabe Y, Hiroshige K, Kinukawa N, Nakamuta M, Nawata H. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C. Med Sci Monit 2000; 6: 692-698
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
12. Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, Lefebvre V, Van Hattum J, Hen-rion J, Delwaide J, Hansen BE, Schalm SW, For The Benelux Study Group On Treatment Of Chronic Hepatitis C. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40: 689-695
13. Banner BF, Allan C, Smith L, Savas L, Bonkovsky HL. Effect of interferon therapy on bile duct inflammation in hepatitis C. Virchows Arch 1996; 428: 253-259
14. Trombetti A, Giostra E, Mentha G, Negro F, Rizzoli R. Lack of evidence for ribavirin-induced bone loss. Hepatology 2002; 36: 255-257
15. Oreffo RO, Romberg S, Virdi AS, Joyner CJ, Berven S, Triffitt JT. Effects of interferon alpha on human osteoprogenitor cell growth and differentiation in vitro. J Cell Biochem 1999; 74: 372-385
16. Lee J, Kim JH, Kim K, Jin HM, Lee KB, Chung DJ, Kim N. Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/ RANKL. Mol Cell Biochem 2007; 296: 17-24